Inhibition of the JNK pathway has been proposed as a potential therapeutic way for treating beta cell failure in type 2 diabetes and some efforts are currently maintained to identify novel JNK inhibitors [51]. This evidence concerns the gene MAPK8 and type 2 diabetes mellitus.